X
More than 60,000 patients use Brite
4.6 stars
Your health finally understandable with Brite
1
Enter email and you're done. No subscription, no credit card.
2
Search, tap and you're done. Over 3,400 medicines.
3
Check, remind, get an overview.
Sarah K., 34
I finally understand my therapy. The app reminds me, answers my questions — and I don't feel alone with it anymore.
Aripiprazole is an atypical antipsychotic and acts as a partial agonist at the dopamine receptor: it dampens the signal where too much dopamine is about, and activates it where too little arrives. From that follows a side effect profile that differs markedly from older substances and from other atypical ones. The typical side effect is not tiredness but an agonising inner restlessness.
See more detail.gif)
Record your doses, your restlessness and your sleep over the weeks — free in the brite app.
| Property | Details |
|---|---|
| Active ingredient | Aripiprazole |
| ATC code | N05AX12 |
| Drug class | Atypical antipsychotic; partial agonist at the dopamine D2 receptor (a “dopamine stabiliser”) |
| Dosage forms | Tablets and orodispersible tablets (usually 5 to 30 mg), oral solution, depot injection given monthly |
| Half-life | Around 75 hours, and longer still for the active breakdown product — a stable blood level is only reached after about two weeks |
| Maximum daily dose | 30 mg according to the SmPC; your individual dose is set by the treating practice |
| Onset of effect | First effects often after a few days; a full assessment takes several weeks |
| Metabolism | Via the liver enzymes CYP2D6 and CYP3A4 — hence the relevant interactions |
| Prescription status | Prescription-only medicine |
| Notable feature | Little sedation and a more favourable metabolic profile than many other atypical antipsychotics; the typical side effect is inner restlessness (akathisia) |
Most antipsychotics block the dopamine D2 receptor completely: they switch the signal off. Aripiprazole does something else. It binds to the same receptor, but triggers a weakened signal there. That is called partial agonism.¹
The effect depends on how much of the body's own dopamine is about at the time:
Aripiprazole also acts at serotonin receptors, which contributes to its effect on mood. From this mechanism follow the three properties that shape everyday life: less sedation than with strongly dampening substances, less of a rise in prolactin — and, as the flip side, a marked tendency towards inner restlessness. Anyone expecting a calming effect often experiences the opposite here.
Aripiprazole is used in several psychiatric conditions. In Germany it is licensed above all for the treatment of schizophrenia, as well as for moderate to severe manic episodes in bipolar disorder and to prevent new manic episodes.¹,²
A question that comes up often is its use in depression. Precision is worth it here: internationally, aripiprazole has been studied as an add-on medicine alongside an antidepressant where the antidepressant alone does not work well enough. In Germany, however, aripiprazole is not licensed for this add-on treatment; using it this way is off-label use in the individual case and has to be discussed explicitly. Among the substances licensed here as an add-on in depression is quetiapine.³
Whether and when such an extension makes sense is always decided by the treating practice or clinic — together with you and on the basis of the guidelines.
The figures below describe what the SmPC gives as the usual approach. They are not a dosing instruction.
The depot injection. Aripiprazole is also available as a depot injection, given into the muscle as a rule once a month. The advantage is obvious: no daily tablet, nothing to forget, an even blood level. So is the drawback: if a side effect appears, it cannot be cut short by leaving out the next tablet — the drug stays in the body for weeks. Before switching to a depot, it is therefore checked whether the substance was tolerated as a tablet.
So that at your next appointment it is clear when what started.
Aripiprazole is regarded as comparatively well tolerated — but “tolerated differently” puts it better. The typical complaints differ markedly from those of strongly dampening substances.
If there is one side effect you have to know about with aripiprazole, this is it. Akathisia (restlessness that makes sitting still impossible) is an agonising feeling of being inwardly driven, coupled with an urge to move. It typically appears in the first days to weeks and after every increase in dose.¹,²
The real problem is not how often it happens but how easily it is mistaken for something else: akathisia is regularly read as anxiety, as nervousness or as a worsening of the underlying illness. The obvious response — raising the dose — then makes it worse. Knowing the signs lets you prevent that.
For the general picture of this symptom — and which other causes come into question — see the article on inner restlessness.
This side effect is rare, but it can cost people their livelihood — and hardly anyone expects it. On aripiprazole, a newly arising or markedly increased urge to give in to certain impulses has been described. The authorities have therefore added an explicit warning to the product information.⁴
Warning signs in everyday life are secret movements on bank accounts, new accounts or loans, online activity that is kept quiet, sudden activity at night and unusual spending. This is not a weakness of character and not a relapse into mania — it can be an effect of the medicine, and that is exactly how it should be discussed.
Aripiprazole is broken down by two liver enzymes: CYP2D6 and CYP3A4. Anything that slows these enzymes down or revs them up changes the blood level — upwards with more side effects, downwards with a loss of effect.
| Combination | Consequence | What to do |
|---|---|---|
| Strong CYP2D6 inhibitors (e.g. certain antidepressants such as fluoxetine or paroxetine) | Aripiprazole levels rise, with more restlessness and more side effects | Dose adjustment by the practice; plan the combination deliberately |
| Strong CYP3A4 inhibitors (e.g. certain antifungals and macrolide antibiotics) | Levels rise markedly | The dose is usually reduced for as long as the combination runs |
| CYP3A4 inducers (e.g. carbamazepine, St John's wort) | Levels fall and the effect can be lost | Never add St John's wort on your own; checking back is a must |
| Grapefruit and grapefruit juice | Can inhibit the breakdown via CYP3A4 | Avoid it or clarify with your pharmacy, see grapefruit and medications |
| Other sedating agents, sleeping tablets, opioids | Increased tiredness and risk of falls | Combine only after consultation |
| Alcohol | Increases drowsiness and impairs judgement, and can destabilise the underlying illness | Best avoided, see medications and alcohol |
Some people break aripiprazole down more slowly for genetic reasons (“poor CYP2D6 metabolisers”). For them the SmPC provides for a reduced dose. Check new combinations in the guide drug interactions or directly in the interaction check in the brite app — particularly if several specialties are prescribing for you (polypharmacy).
All atypical antipsychotics act on the dopamine and serotonin systems, but they differ markedly in their side effect profiles. The decisive question is not “stronger” or “weaker” but: which side effect can you most readily live with?²
| Feature | Aripiprazole | Other atypical antipsychotics by comparison |
|---|---|---|
| Sedation | Low — it can even disturb sleep at first | Olanzapine and quetiapine are markedly more dampening |
| Weight and metabolism | More favourable, but not neutral | Olanzapine is regarded as the hardest on metabolism in the group |
| Prolactin | Tends to fall — cycle disturbances and milk flow are rarer | Risperidone and amisulpride typically make prolactin rise |
| Inner restlessness (akathisia) | Markedly commoner — that is the price of partial agonism | Rarer with dampening substances |
| Dosage forms | Tablet, orodispersible tablet, oral solution, monthly depot | Depot forms exist for several other substances too |
In bipolar disorder, aripiprazole is often combined with mood stabilisers such as lithium or lamotrigine; in the treatment of depression an antidepressant such as sertraline usually comes first. Which combination fits depends on the course of the illness, on previous experience and on tolerability — and it is a decision for the treating practice, not for the internet.
Aripiprazole is not addictive — stopping abruptly is still not a good idea. Two things can happen: discontinuation phenomena such as restlessness, insomnia, nausea and sweating, and above all a relapse of the underlying illness, often with weeks of delay. Because of the long half-life the blood level falls slowly, so that the connection is barely recognisable later on. A planned, step-by-step taper with appointments and an emergency plan is therefore the safe route: stopping medications.
In older people the dose is lower, because dizziness, drops in blood pressure and falls are more common. One special warning matters: in older people with dementia, antipsychotics as a group are associated with increased mortality and an increased risk of stroke. Aripiprazole is not licensed for treating behavioural problems in dementia. The guide medications in old age gives you your bearings on the subject.¹
That is the commonest and the most important question with this substance. A good clue is the timing: if the restlessness began within days of starting treatment or of a dose increase, much speaks for akathisia. A second clue is the quality: akathisia feels physical and forces you to move, whereas anxiety tends to circle in your thoughts. The two can overlap. Note down when it started, the time of day and any connection with changes of dose — and bring those notes with you. That is exactly what a health log is for.
Usually the opposite is right. Because the substance is more activating, it is often moved to the morning. But do not change the time on your own; raise it instead — not least because sleep problems in mental illness can have several causes. What else helps is set out in the guide sleeping pills: what really helps?.
It is less likely than with some other atypical antipsychotics — but it happens. It makes sense to have your weight, blood sugar and blood lipids checked before treatment starts and then regularly, rather than reacting once ten kilos are on. Exercise and a deliberate eating routine work preventively here, not just as repair work.
That you are doing well is often the result of the treatment. After a psychosis or a manic episode in particular, the risk of relapse after stopping is considerable, and because of the long half-life the relapse often comes only after weeks — at which point it looks like coincidence. If you want to stop, that is a legitimate goal: planned, slow, supported and with a plan for emergencies.
The interaction check shows what shifts your aripiprazole levels.
Record your doses, your restlessness and your sleep, and show them at your appointment. Free.
Create medication plan